Infographic

Industry-sponsored clinical trials a boon to US state economies

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Darren415)
(Image: Getty/Darren415)

Related tags: Clinical trials, PhRMA

Biopharmaceutical manufacturers in 2017 invested approximately $15.2bn at clinical trial sites around the country – resulting in a total economic impact of more than $42bn, says PhRMA director of public affairs.

These numbers are according to a new report from TEConomy Partners, supported by PhRMA, which estimates industry-sponsored clinical trial activity in the US in 2017.

The calculation of the overall economic impact includes the “ripple effect”​ of expenditures by clinical trial vendors and contractors as well as spending by industry and vendor employees, per the report.

“Most importantly, some 920,172 patients participated in more than 4,500 industry-led clinical trials across the United States during that same period,”​ Tiffany Haverly, director of public affairs, PhRMA, told us.

Haverly noted that some states “not typically associated with a large biopharmaceutical industry presence”​ supported many trials. For example, 1,016 in Tennessee.

According to the report, only six states had fewer than 100 clinical trials active in 2017.

The top five states with the most active trials were California, Florida, Texas, New York, and North Carolina.

“The biopharmaceutical industry brings profound value to patients through new treatments and cures for society’s most devastating and costly diseases and conditions, providing millions of patients with treatment options they would not otherwise have,”​ said Haverly.

“This report further underscores the positive impact industry-led clinical trials have on patients and local economies.”

Related topics: Clinical Development, Phase I-II

Related news

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers

Follow us

Products

View more

Webinars